NCT03291951 (FORCE) is a NA clinical trial of Resistance training in Resistance Training, sponsored by Kaiser Permanente.

Who is sponsoring NCT03291951?

NCT03291951 is sponsored by Kaiser Permanente.

What drugs are being tested in NCT03291951?

Interventions in NCT03291951: Resistance training.

What condition does NCT03291951 study?

NCT03291951 studies Resistance Training, Colon Cancer, Chemotherapy Effect.

Is NCT03291951 still recruiting?

NCT03291951 is currently completed. Last updated 28 July 2022.

Last reviewed 2022-07-28 · How we verify

NCT03291951: FORCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

Completed NA Last updated 28 July 2022

What this trial tests

NA trial testing Resistance training in Resistance Training in 183 participants. Completed in 21 March 2022.

Timeline

23 February 2018

Primary endpoint
21 March 2022

21 March 2022

Quick facts

Lead sponsor	Kaiser Permanente
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	183
Start date	23 February 2018
Primary completion	21 March 2022
Estimated completion	21 March 2022
Sites	3 locations across United States

Drugs / interventions tested

Resistance training

Conditions studied

Resistance Training — all drugs for Resistance Training →
Colon Cancer — all drugs for Colon Cancer →
Chemotherapy Effect — all drugs for Chemotherapy Effect →

Sponsor

Kaiser Permanente — full company profile →

Who can join

18 and older, any sex, with Resistance Training or Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

FORCE is a randomized home-based resistance training/strength training (RT) intervention study for Stage II and III colon cancer patients undergoing chemotherapy. Participants will be 180 newly diagnosed Stage II and III colon cancer patients from Kaiser Permanente of Northern California (KPNC), the Penn State Cancer Institute (PSCI), and the Dana Farber Cancer Institute (DFCI). The intervention will begin within the first weeks of adjuvant chemotherapy and continue exercise through the completion of post-operative chemotherapy. Specifically, the investigators will examine between group differences for RT versus waitlist control for chemotherapy outcomes including dose delays, dose reductions, early stoppage and Grade 3 and 4 toxicities. The investigators will also study changes in muscle mass (MM) and changes in specific inflammatory markers (e.g. CRP, IL-6 and TNF-RII) as potential markers of change in response to RT. To determine effects of change of MM on chemotherapy-specific drug clearance, the investigators will examine the impact body composition changes on the pharmacokinetics (PK) of 5-FU and oxaliplatin, two of the most commonly used drugs for colon cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The evolution of body composition in oncology-epidemiology, clinical trials, and the future of patient care: facts and numbers.
Brown JC, Cespedes Feliciano EM, Caan BJ. · · 2018 · cited 135× · PMID 30637983 · DOI 10.1002/jcsm.12379
Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Kurk S, Peeters P, Stellato R, Dorresteijn B, et al · · 2019 · cited 85× · PMID 31094083 · DOI 10.1002/jcsm.12436
Effect of exercise on colorectal cancer prevention and treatment.
Oruç Z, Kaplan MA. · · 2019 · cited 72× · PMID 31139306 · DOI 10.4251/wjgo.v11.i5.348
Cancer- and Chemotherapy-Induced Musculoskeletal Degradation.
Sturgeon KM, Mathis KM, Rogers CJ, Schmitz KH, et al · · 2019 · cited 30× · PMID 30918923 · DOI 10.1002/jbm4.10187
Clinical implications of low skeletal muscle mass in early-stage breast and colorectal cancer.
Cespedes Feliciano E, Chen WY. · · 2018 · cited 29× · PMID 29860952 · DOI 10.1017/s0029665118000423
Muscle wasting in cancer: opportunities and challenges for exercise in clinical cancer trials.
Fairman CM, Lønbro S, Cardaci TD, VanderVeen BN, et al · · 2022 · cited 28× · PMID 36118249 · DOI 10.1002/rco2.56
Effect of home-based resistance training on chemotherapy relative dose intensity and tolerability in colon cancer: The FORCE randomized control trial.
Caan BJ, Brown JC, Brown JC, Lee C, et al · · 2024 · cited 12× · PMID 38265970 · DOI 10.1002/cncr.35204
Advances in Adherence Reporting of Resistance Training in a Clinical Trial during Adjuvant Chemotherapy for Colon Cancer.
Campbell KL, Brown JC, Lee C, Weltzien E, et al · · 2024 · cited 8× · PMID 38233992 · DOI 10.1249/mss.0000000000003395

Verify or expand the search:

Other trials of Resistance training

Trials testing the same drug.

NCT07166198 — Mitigating Neural Hypoexcitability and Weakness During Disuse in Women · NA · not yet recruiting
NCT07411625 — Preoperative Rehabilitation for Patient With an ACL Injury · NA · recruiting
NCT07484776 — Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer · NA · active not recruiting
NCT07341698 — Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplant · NA · recruiting
NCT07058818 — Tailored Resistance Training After Adverse Pregnancy Outcomes · NA · completed

Other recruiting trials for Resistance Training

Currently open trials in the same condition.

NCT06360536 — Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women · NA · recruiting
NCT06765486 — Exercise-Induced Hypoalgesia Differences Between Upper and Lower Limbs Resistance Training Interventions · NA · recruiting
NCT06679491 — Impact of Menstrual Cycle-Based Resistance Training on Neuromuscular Performance in Female Athletes · NA · recruiting
NCT07347912 — Group-based Resistance Training for Adults With Down Syndrome · NA · active not recruiting
NCT06536803 — Effects of High Load Strength Training With and Without Tissue Specific Planter Facia Stretching With Planter Fasciitis · NA · recruiting

Other Kaiser Permanente trials

Trials by the same sponsor.

NCT07522645 — Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Dis · NA · not yet recruiting
NCT07474038 — AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment · NA · enrolling by invitation
NCT07467668 — Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure · NA · not yet recruiting
NCT07216859 — Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI) · NA · not yet recruiting
NCT07264062 — MetSense Pilot and Feasibility · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03291951 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kaiser Permanente
Last refreshed: 28 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03291951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing